# E-DRUG: Osteoporosis and Oestrogens / Fosamox (cont'd) **URL:** \ **Category:** e-drug\ **Created:** [May 8, 1998, 10:04am UTC](https://talk.edrugplus.org/t/e-drug-osteoporosis-and-oestrogens-fosamox-contd/2577 "1998-05-08T10:04:12Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![mddah](https://avatars.discourse-cdn.com/v4/letter/m/f0a364/32.png) [@mddah](https://talk.edrugplus.org/u/mddah)\ **Post date:** [May 8, 1998, 10:04am UTC](https://talk.edrugplus.org/t/e-drug-osteoporosis-and-oestrogens-fosamox-contd/2577/1 "1998-05-08T10:04:12Z")
E-drug: Osteoporosis and Oestrogens / Fosamox (cont'd) --------------------------------------------- In addition to the consensus statement on osteoporosis treatment mentioned by Mark Dunn in Tasmania, there is a systematic review of the effects of estrogens on fracture rates (and separate reviews of the impact on bone mineral density/content) which were part of a report to the Australian Institute of Health and Welfare. Biphosphonates were not included. The information is a little out of date, but we have some spare copies of the report in Newcastle for those who are interested. There are reviews of Calcium and Vitamin D in the Cochrane Library, and I think reviews of estrogens and bisphosphonates are pending. There are very few comparative studies of estrogens and alternative treatments but a comparative trial of estrogen and alendronate has been published recently (New England Journal of Medicine. 338(8):485-492, 1998 February 19) David Henry, Discipline of Clinical Pharmacology, Faculty of Medicine and Health Sciences, The University of Newcastle, Newcastle Mater Hospital, Waratah, NSW, AUSTRALIA Phone +61 (0)49 211856 Fax +61 (0)49 602088 Home +61 (0)49 505576 e-mail: mddah@mail.newcastle.edu.au -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.